{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:48:34Z","timestamp":1787028514735,"version":"build-2736575974"},"reference-count":154,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2023,6,7]],"date-time":"2023-06-07T00:00:00Z","timestamp":1686096000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Psoriasis is a chronic inflammatory disease with an established genetic background. The HLA-Cw*06 allele and different polymorphisms in genes involved in inflammatory responses and keratinocyte proliferation have been associated with the development of the disease. Despite the effectiveness and safety of psoriasis treatment, a significant percentage of patients still do not achieve adequate disease control. Pharmacogenetic and pharmacogenomic studies on how genetic variations affect drug efficacy and toxicity could provide important clues in this respect. This comprehensive review assessed the available evidence for the role that those different genetic variations may play in the response to psoriasis treatment. One hundred fourteen articles were included in this qualitative synthesis. VDR gene polymorphisms may influence the response to topical vitamin D analogs and phototherapy. Variations affecting the ABC transporter seem to play a role in methotrexate and cyclosporine outcomes. Several single-nucleotide polymorphisms affecting different genes are involved with anti-TNF-\u03b1 response modulation (TNF-\u03b1, TNFRSF1A, TNFRSF1B, TNFAIP3, FCGR2A, FCGR3A, IL-17F, IL-17R, and IL-23R, among others) with conflicting results. HLA-Cw*06 has been the most extensively studied allele, although it has only been robustly related to the response to ustekinumab. However, further research is needed to firmly establish the usefulness of these genetic biomarkers in clinical practice.<\/jats:p>","DOI":"10.3390\/ijms24129850","type":"journal-article","created":{"date-parts":[[2023,6,8]],"date-time":"2023-06-08T02:58:32Z","timestamp":1686193112000},"page":"9850","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Genetic Influence on Treatment Response in Psoriasis: New Insights into Personalized Medicine"],"prefix":"10.3390","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0348-5421","authenticated-orcid":false,"given":"Emilio","family":"Berna-Rico","sequence":"first","affiliation":[{"name":"Department of Dermatology, Hospital Universitario Ram\u00f3n y Cajal, IRYCIS, Colmenar Viejo km 9.100, 28034 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Perez-Bootello","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Hospital Universitario Ram\u00f3n y Cajal, IRYCIS, Colmenar Viejo km 9.100, 28034 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5587-1204","authenticated-orcid":false,"given":"Carlota","family":"Abbad-Jaime de Aragon","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Hospital Universitario Ram\u00f3n y Cajal, IRYCIS, Colmenar Viejo km 9.100, 28034 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alvaro","family":"Gonzalez-Cantero","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Hospital Universitario Ram\u00f3n y Cajal, IRYCIS, Colmenar Viejo km 9.100, 28034 Madrid, Spain"},{"name":"Faculty of Medicine, Universidad Francisco de Vitoria, 28223 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,6,7]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S0140-6736(14)61909-7","article-title":"Psoriasis","volume":"386","author":"Boehncke","year":"2015","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/jid.2012.339","article-title":"Global Epidemiology of Psoriasis: A Systematic Review of Incidence and Prevalence","volume":"133","author":"Parisi","year":"2013","journal-title":"J. Investig. Dermatol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"743180","DOI":"10.3389\/fmed.2021.743180","article-title":"The Global, Regional, and National Burden of Psoriasis: Results and Insights From the Global Burden of Disease 2019 Study","volume":"8","author":"Damiani","year":"2021","journal-title":"Front. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"3140682","DOI":"10.1155\/2018\/3140682","article-title":"Psoriasis and Respiratory Comorbidities: The Added Value of Fraction of Exhaled Nitric Oxide as a New Method to Detect, Evaluate, and Monitor Psoriatic Systemic Involvement and Therapeutic Efficacy","volume":"2018","author":"Santus","year":"2018","journal-title":"BioMed Res. Int."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Conic, R.R., Damiani, G., Schrom, K.P., Ramser, A.E., Zheng, C., Xu, R., McCormick, T.S., and Cooper, K.D. (2020). Psoriasis and Psoriatic Arthritis Cardiovascular Disease Endotypes Identified by Red Blood Cell Distribution Width and Mean Platelet Volume. J. Clin. Med., 9.","DOI":"10.3390\/jcm9010186"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jaad.2016.07.064","article-title":"Psoriasis and comorbid diseases","volume":"76","author":"Takeshita","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.jaad.2018.07.059","article-title":"Psoriasis causes as much disability as other major medical diseases","volume":"82","author":"Feldman","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1016\/j.jaad.2018.12.037","article-title":"All-cause and cause-specific mortality in psoriasis: A systematic review and meta-analysis","volume":"80","author":"Dhana","year":"2019","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1111\/j.1365-2133.2010.09941.x","article-title":"Cause-specific mortality in patients with severe psoriasis: A population-based cohort study in the U.K.: Cause-specific mortality in patients with severe psoriasis","volume":"163","author":"Abuabara","year":"2010","journal-title":"Br. J. Dermatol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.jaut.2015.07.008","article-title":"The immunogenetics of Psoriasis: A comprehensive review","volume":"64","author":"Harden","year":"2015","journal-title":"J. Autoimmun."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1086\/503821","article-title":"Sequence and Haplotype Analysis Supports HLA-C as the Psoriasis Susceptibility 1 Gene","volume":"78","author":"Nair","year":"2006","journal-title":"Am. J. Hum. Genet."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"726","DOI":"10.3109\/08820139.2013.810241","article-title":"Associations between interleukin-23R and interleukin-12B polymorphisms and psoriasis susceptibility: A meta-analysis","volume":"42","author":"Lee","year":"2013","journal-title":"Immunol. Investig."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"13554","DOI":"10.1111\/jcmm.15742","article-title":"Overview of the molecular determinants contributing to the expression of Psoriasis and Psoriatic Arthritis phenotypes","volume":"24","author":"Caputo","year":"2020","journal-title":"J. Cell. Mol. Med."},{"key":"ref_14","first-page":"613086","article-title":"Genetics of Psoriasis and Pharmacogenetics of Biological Drugs","volume":"2013","author":"Cabaleiro","year":"2013","journal-title":"Autoimmune Dis."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Rendon, A., and Sch\u00e4kel, K. (2019). Psoriasis Pathogenesis and Treatment. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20061475"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Membrive Jim\u00e9nez, C., P\u00e9rez Ram\u00edrez, C., S\u00e1nchez Mart\u00edn, A., Vieira Maroun, S., Arias Santiago, S.A., Ram\u00edrez Tortosa, M.D.C., and Jim\u00e9nez Morales, A. (2021). Influence of Genetic Polymorphisms on Response to Biologics in Moderate-to-Severe Psoriasis. J. Pers. Med., 11.","DOI":"10.3390\/jpm11040293"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/jdv.13542","article-title":"Consensus document on the evaluation and treatment of moderate-to-severe psoriasis: Psoriasis Group of the Spanish Academy of Dermatology and Venereology","volume":"30","author":"Puig","year":"2016","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_18","first-page":"CD011535","article-title":"Systemic pharmacological treatments for chronic plaque psoriasis: A network meta-analysis. Cochrane Skin Group, editor","volume":"8","author":"Sbidian","year":"2022","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s40257-015-0131-y","article-title":"Immunogenicity of Biologic Treatments for Psoriasis: Therapeutic Consequences and the Potential Value of Concomitant Methotrexate","volume":"16","author":"Farhangian","year":"2015","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Mu\u00f1oz-Aceituno, E., Martos-Cabrera, L., Ovejero-Benito, M.C., Reolid, A., Abad-Santos, F., and Daud\u00e9n, E. (2020). Pharmacogenetics Update on Biologic Therapy in Psoriasis. Medicina, 56.","DOI":"10.3390\/medicina56120719"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s40257-017-0322-9","article-title":"Pharmacogenetics and Pharmacogenomics in Moderate-to-Severe Psoriasis","volume":"19","author":"Reolid","year":"2018","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Caputo, V., Strafella, C., Cosio, T., Lanna, C., Campione, E., Novelli, G., Giardina, E., and Cascella, R. (2021). Pharmacogenomics: An Update on Biologics and Small-Molecule Drugs in the Treatment of Psoriasis. Genes, 12.","DOI":"10.3390\/genes12091398"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1111\/bjd.15753","article-title":"A systematic review of pharmacogenetic studies on the response to biologics in patients with psoriasis","volume":"178","author":"Coenen","year":"2018","journal-title":"Br. J. Dermatol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1046\/j.1523-1747.1998.00128.x","article-title":"Vitamin D Receptor Polymorphism and Calcipotriol Response in Patients with Psoriasis","volume":"110","author":"Mee","year":"1998","journal-title":"J. Investig. Dermatol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.jdermsci.2004.11.008","article-title":"Does the determination of the Bb vitamin D receptor genotype identify psoriasis vulgaris patients responsive to topical tacalcitol?","volume":"37","author":"Giomi","year":"2005","journal-title":"J. Dermatol. Sci."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0923-1811(02)00073-7","article-title":"Polymorphisms of vitamin D receptor gene in Japanese patients with psoriasis vulgaris","volume":"30","author":"Saeki","year":"2002","journal-title":"J. Dermatol. Sci."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1097\/01213011-200505000-00011","article-title":"Vitamin D receptor gene polymorphisms, particularly the novel A-1012G promoter polymorphism, are associated with vitamin D3 responsiveness and non-familial susceptibility in psoriasis","volume":"15","author":"Halsall","year":"2005","journal-title":"Pharm. Genom."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s00403-007-0782-5","article-title":"Polymorphisms of vitamin D receptor gene in Turkish familial psoriasis patients","volume":"299","author":"Karaduman","year":"2007","journal-title":"Arch. Dermatol. Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"CR661","DOI":"10.12659\/MSM.883544","article-title":"Vitamin D receptor gene polymorphisms and haplotypes (Apa I, Bsm I, Fok I, Taq I) in Turkish psoriasis patients","volume":"18","author":"Acikbas","year":"2012","journal-title":"Med. Sci. Monit."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.jdermsci.2015.06.014","article-title":"VDR gene polymorphisms are associated with the clinical response to calcipotriol in psoriatic patients","volume":"79","author":"Zhao","year":"2015","journal-title":"J. Dermatol. Sci."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.jaad.2019.04.042","article-title":"Joint American Academy of Dermatology\u2013National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis with phototherapy","volume":"81","author":"Elmets","year":"2019","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"192","DOI":"10.4103\/ijd.IJD_114_18","article-title":"Peroxisome proliferator-activated receptor-\u03b3 gene polymorphism in psoriasis and its relation to obesity, metabolic syndrome, and narrowband ultraviolet B response: A case\u2013control study in Egyptian patients","volume":"64","author":"Seleit","year":"2019","journal-title":"Indian J. Dermatol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1111\/phpp.12395","article-title":"Effect of polymorphisms in IL-12B p40, IL-17A and IL-23 A\/G genes on the response of psoriatic patients to narrowband UVB","volume":"34","author":"Youssef","year":"2018","journal-title":"Photodermatol. Photoimmunol. Photomed."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.humimm.2018.02.003","article-title":"IL12B, IL23A, IL23R and HLA-C*06 genetic variants in psoriasis susceptibility and response to treatment","volume":"79","author":"Bojko","year":"2018","journal-title":"Hum. Immunol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1159\/000448090","article-title":"IL17A and IL17F Gene Polymorphism Association with Psoriasis Risk and Response to Treatment in a Polish Population","volume":"232","author":"Ostasz","year":"2016","journal-title":"Dermatology"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1111\/exd.12577","article-title":"IL6 \u2212174G>C polymorphism is associated with an increased risk of psoriasis but not response to treatment","volume":"24","author":"Ostasz","year":"2015","journal-title":"Exp. Dermatol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1111\/j.1365-2133.2007.08209.x","article-title":"Melanocortin 1 receptor (MC1R) genotype influences erythemal sensitivity to psoralen\u2013ultraviolet A photochemotherapy","volume":"157","author":"Smith","year":"2007","journal-title":"Br. J. Dermatol."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Lesiak, A., W\u00f3dz, K., Ci\u0105\u017cy\u0144ska, M., Skibinska, M., Waszczykowski, M., Ci\u0105\u017cy\u0144ski, K., Olejniczak-Staruch, I., Sobolewska-Sztychny, D., and Narbutt, J. (2021). TaaI\/Cdx-2 AA Variant of VDR Defines the Response to Phototherapy amongst Patients with Psoriasis. Life, 11.","DOI":"10.3390\/life11060567"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1111\/j.1365-2133.2010.09985.x","article-title":"Clinical and genetic predictors of response to narrowband ultraviolet B for the treatment of chronic plaque psoriasis: Predictors of response to NB-UVB for psoriasis","volume":"163","author":"Ryan","year":"2010","journal-title":"Br. J. Dermatol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1016\/j.jaad.2020.02.044","article-title":"Joint American Academy of Dermatology\u2013National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies","volume":"82","author":"Menter","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1038\/sj.jid.5700808","article-title":"Polymorphisms in Folate, Pyrimidine, and Purine Metabolism Are Associated with Efficacy and Toxicity of Methotrexate in Psoriasis","volume":"127","author":"Campalani","year":"2007","journal-title":"J. Investig. Dermatol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1038\/jid.2008.16","article-title":"Genetic Variation in Efflux Transporters Influences Outcome to Methotrexate Therapy in Patients with Psoriasis","volume":"128","author":"Warren","year":"2008","journal-title":"J. Investig. Dermatol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"114643","DOI":"10.1016\/j.biopha.2023.114643","article-title":"Overcoming Cancer Multi-drug Resistance (MDR): Reasons, mechanisms, nanotherapeutic solutions, and challenges","volume":"162","author":"Duan","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1007\/s00228-017-2255-x","article-title":"Pharmacogenetic markers to predict the clinical response to methotrexate in south Indian Tamil patients with psoriasis","volume":"73","author":"Indhumathi","year":"2017","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1111\/ced.13100","article-title":"HLA-Cw6-positive patients with psoriasis show improved response to methotrexate treatment","volume":"42","author":"West","year":"2017","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_46","first-page":"1241","article-title":"The HLA-Cw*06 allele may predict the response to methotrexate (MTX) treatment in Chinese arthritis-free psoriasis patients","volume":"315","author":"Mao","year":"2023","journal-title":"Arch. Dermatol. Res."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1111\/jdv.16440","article-title":"The impacts of gene polymorphisms on methotrexate in Chinese psoriatic patients","volume":"34","author":"Chen","year":"2020","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/s41397-018-0047-z","article-title":"Genetic markers in methotrexate treatments","volume":"18","author":"Giletti","year":"2018","journal-title":"Pharmacogenom. J."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"111456","DOI":"10.1016\/j.biopha.2021.111456","article-title":"Polymorphisms in GNMT and DNMT3b are associated with methotrexate treatment outcome in plaque psoriasis","volume":"138","author":"Marko","year":"2021","journal-title":"Biomed. Pharmacother."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Yang, W., Huang, Q., Han, L., Wang, B., Yawalkar, N., Zhang, Z., and Yan, K. (2022). B7-H4 Polymorphism Influences the Prevalence of Diabetes Mellitus and Pro-Atherogenic Dyslipidemia in Patients with Psoriasis. J. Clin. Med., 11.","DOI":"10.3390\/jcm11216235"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1159\/000514072","article-title":"The Impact of ANxA6 Gene Polymorphism on the Efficacy of Methotrexate Treatment in Psoriasis Patients","volume":"237","author":"Fan","year":"2021","journal-title":"Dermatology"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"167","DOI":"10.4103\/jewd.jewd_6_21","article-title":"Il17A (rs2275913 G>A) and IL17F (rs2397084 T>C) gene polymorphisms: Relation to psoriasis risk and response to methotrexate","volume":"18","author":"Hamza","year":"2021","journal-title":"J. Egypt. Womens Dermatol. Soc."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1111\/bjd.17704","article-title":"TT genotype of rs10036748 in TNIP 1 shows better response to methotrexate in a Chinese population: A prospective cohort study","volume":"181","author":"Yan","year":"2019","journal-title":"Br. J. Dermatol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jdermsci.2018.06.009","article-title":"Genetic polymorphism predicting Methotrexate efficacy in Chinese patients with psoriasis vulgaris","volume":"93","author":"Kuang","year":"2019","journal-title":"J. Dermatol. Sci."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"e898","DOI":"10.1111\/jdv.17544","article-title":"A Genome-wide association study identified HLA-C associated with the effectiveness of methotrexate for psoriasis treatment","volume":"35","author":"Zhang","year":"2021","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/tpj.2014.23","article-title":"A pharmacogenetic study of ABCB1 polymorphisms and cyclosporine treatment response in patients with psoriasis in the Greek population","volume":"14","author":"Vasilopoulos","year":"2014","journal-title":"Pharmacogenom. J."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Chernov, A., Kilina, D., Smirnova, T., and Galimova, E. (2022). Pharmacogenetic Study of the Impact of ABCB1 Single Nucleotide Polymorphisms on the Response to Cyclosporine in Psoriasis Patients. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14112441"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/s41397-022-00291-7","article-title":"Protein network and pathway analysis in a pharmacogenetic study of cyclosporine treatment response in Greek patients with psoriasis","volume":"23","author":"Antonatos","year":"2023","journal-title":"Pharmacogenom. J."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1111\/j.1468-3083.2009.03181.x","article-title":"Vascular endothelial growth factor in psoriasis: An indicator of disease severity and control","volume":"23","author":"Nofal","year":"2009","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/sj.jid.5700096","article-title":"Interaction between Genetic Control of Vascular Endothelial Growth Factor Production and Retinoid Responsiveness in Psoriasis","volume":"126","author":"Young","year":"2006","journal-title":"J. Investig. Dermatol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"181","DOI":"10.2217\/pme-2017-0085","article-title":"The polymorphisms of growth factor genes (VEGFA & EGF) were associated with response to acitretin in psoriasis","volume":"15","author":"Chen","year":"2018","journal-title":"Pers. Med."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"30","DOI":"10.5021\/ad.2016.28.1.30","article-title":"Genetic Risk Factors for Psoriasis in Turkish Population: -1540 C\/A, -1512 Ins18, and +405 C\/G Polymorphisms within the Vascular Endothelial Growth Factor Gene","volume":"28","author":"Bozduman","year":"2016","journal-title":"Ann. Dermatol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"13182","DOI":"10.1038\/s41598-018-31352-2","article-title":"Polymorphisms of SLCO1B1 rs4149056 and SLC22A1 rs2282143 are associated with responsiveness to acitretin in psoriasis patients","volume":"8","author":"Chen","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"937490","DOI":"10.3389\/fphar.2022.937490","article-title":"The Inflammatory Factor SNP May Serve as a Promising Biomarker for Acitretin to Alleviate Secondary Failure of Response to TNF-a Monoclonal Antibodies in Psoriasis","volume":"13","author":"Lin","year":"2022","journal-title":"Front. Pharmacol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1111\/dth.12140","article-title":"HLA-G 14-bp polymorphism: A possible marker of systemic treatment response in psoriasis vulgaris? Preliminary results of a retrospective study: HLA-G 14-bp polymorphism and therapy in psoriasis","volume":"27","author":"Borghi","year":"2014","journal-title":"Dermatol. Ther."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"266","DOI":"10.31083\/j.fbl2709266","article-title":"HLA-DQA1 and DQB1 Alleles are Associated with Acitretin Response in Patients with Psoriasis","volume":"27","author":"Zhou","year":"2022","journal-title":"Front. Biosci.-Landmark"},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Zhou, X., He, Y., Kuang, Y., Li, J., Zhang, J., Chen, M., Chen, W., Su, J., Zhao, S., and Liu, P. (2017). Whole Exome Sequencing in Psoriasis Patients Contributes to Studies of Acitretin Treatment Difference. Int. J. Mol. Sci., 18.","DOI":"10.3390\/ijms18020295"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1111\/j.1365-2133.2005.06950.x","article-title":"Apolipoprotein E gene polymorphisms are associated with psoriasis but do not determine disease response to acitretin: ApoE gene polymorphisms, psoriasis and acitretin","volume":"154","author":"Campalani","year":"2006","journal-title":"Br. J. Dermatol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1684\/ejd.2018.3245","article-title":"Association of IL36RN mutations with clinical features, therapeutic response to acitretin, and frequency of recurrence in patients with generalized pustular psoriasis","volume":"28","author":"Zhu","year":"2018","journal-title":"Eur. J. Dermatol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jaad.2015.03.049","article-title":"Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)","volume":"73","author":"Papp","year":"2015","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Verbenko, D.A., Karamova, A.E., Artamonova, O.G., Deryabin, D.G., Rakitko, A., Chernitsov, A., Krasnenko, A., Elmuratov, A., Solomka, V.S., and Kubanov, A.A. (2020). Apremilast Pharmacogenomics in Russian Patients with Moderate-to-Severe and Severe Psoriasis. J. Pers. Med., 11.","DOI":"10.3390\/jpm11010020"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/S0140-6736(05)67566-6","article-title":"Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: A phase III, multicentre, double-blind trial","volume":"366","author":"Reich","year":"2005","journal-title":"Lancet"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s40257-015-0161-5","article-title":"Adalimumab Efficacy in Patients with Psoriasis Who Received or Did Not Respond to Prior Systemic Therapy: A Pooled Post Hoc Analysis of Results from Three Double-Blind, Placebo-Controlled Clinical Trials","volume":"17","author":"Papp","year":"2016","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jaad.2007.09.010","article-title":"Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial","volume":"58","author":"Menter","year":"2008","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1111\/j.1365-2133.2007.08315.x","article-title":"Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION): Adalimumab vs. methotrexate in psoriasis","volume":"158","author":"Saurat","year":"2007","journal-title":"Br. J. Dermatol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1111\/j.1365-2133.2005.06688.x","article-title":"A global phase III randomized controlled trial of etanercept in psoriasis: Safety, efficacy, and effect of dose reduction","volume":"152","author":"Papp","year":"2005","journal-title":"Br. J. Dermatol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.ad.2021.10.003","article-title":"Actualizaci\u00f3n pr\u00e1ctica de las recomendaciones del Grupo de Psoriasis de la Academia Espa\u00f1ola de Dermatolog\u00eda y Venereolog\u00eda (GPS) para el tratamiento de la psoriasis con terapia biol\u00f3gica. Parte 1. \u00abConceptos y manejo general de la psoriasis con terapia biol\u00f3gica\u00bb","volume":"113","author":"Carrascosa","year":"2022","journal-title":"Actas Dermo-Sifiliogr\u00e1ficas"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40257-017-0328-3","article-title":"Choosing First-Line Biologic Treatment for Moderate-to-Severe Psoriasis: What Does the Evidence Say?","volume":"19","author":"Amin","year":"2018","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1007\/s40291-019-00409-x","article-title":"NFKBIZ and CW6 in Adalimumab Response among Psoriasis Patients: Genetic Association and Alternative Transcript Analysis","volume":"23","author":"Batalla","year":"2019","journal-title":"Mol. Diagn. Ther."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1097\/FPC.0000000000000136","article-title":"The Cw6 and late-cornified envelope genotype plays a significant role in anti-tumor necrosis factor response among psoriatic patients","volume":"25","author":"Batalla","year":"2015","journal-title":"Pharmacogenet. Genom."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1111\/bjd.12425","article-title":"The relationship between tumour necrosis factor (TNF)-\u03b1 promoter and IL12B\/IL-23R genes polymorphisms and the efficacy of anti-TNF-\u03b1 therapy in psoriasis: A case-control study","volume":"169","author":"Gallo","year":"2013","journal-title":"Br. J. Dermatol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1016\/j.jaci.2018.11.038","article-title":"HLA-C*06:02 genotype is a predictive biomarker of biologic treatment response in psoriasis","volume":"143","author":"Dand","year":"2019","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1111\/bjd.15005","article-title":"Polymorphisms in CD84, IL12B and TNFAIP3 are associated with response to biologics in patients with psoriasis","volume":"176","author":"Coenen","year":"2017","journal-title":"Br. J. Dermatol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1111\/ced.12323","article-title":"Genetic markers of treatment response to tumour necrosis factor-\u03b1 inhibitors in the treatment of psoriasis","volume":"39","author":"Ryan","year":"2014","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1111\/j.1365-2133.2011.10688.x","article-title":"HLA polymorphism among Chinese patients with chronic plaque psoriasis: Subgroup analysis: HLA polymorphism among Chinese patients with psoriasis","volume":"166","author":"Chiu","year":"2012","journal-title":"Br. J. Dermatol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s40291-017-0261-4","article-title":"HLA-C*06:02 Does Not Predispose to Clinical Response Following Long-Term Adalimumab Treatment in Psoriatic Patients: A Retrospective Cohort Study","volume":"21","author":"Talamonti","year":"2017","journal-title":"Mol. Diagn. Ther."},{"key":"ref_87","first-page":"S71","article-title":"Potential role of HLA-Cw6 in clinical response to anti-tumour necrosis factor alpha and T-cell targeting agents in psoriasis patients","volume":"33","author":"Talamonti","year":"2013","journal-title":"Clin. Drug. Investig."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1097\/FPC.0000000000000233","article-title":"HLA-Cw6 allele, NFkB1 and NFkBIA polymorphisms play no role in predicting response to etanercept in psoriatic patients","volume":"26","author":"Caldarola","year":"2016","journal-title":"Pharmacogenet. Genom."},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Burlando, M., Russo, R., Clapasson, A., Carmisciano, L., Stecca, A., Cozzani, E., and Parodi, A. (2020). The HLA-Cw6 Dilemma: Is It Really an Outcome Predictor in Psoriasis Patients under Biologic Therapy? A Monocentric Retrospective Analysis. J. Clin. Med., 9.","DOI":"10.3390\/jcm9103140"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s40291-016-0198-z","article-title":"A Pharmacogenetic Study of Psoriasis Risk Variants in a Greek Population and Prediction of Responses to Anti-TNF-\u03b1 and Anti-IL-12\/23 Agents","volume":"20","author":"Masouri","year":"2016","journal-title":"Mol. Diagn. Ther."},{"key":"ref_91","first-page":"101879","article-title":"Polymorphisms Associated with Age at Onset in Patients with Moderate-to-Severe Plaque Psoriasis","volume":"2015","author":"Cabaleiro","year":"2015","journal-title":"J. Immunol. Res."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"631","DOI":"10.2217\/pgs-2017-0014","article-title":"Polymorphisms associated with etanercept response in moderate-to-severe plaque psoriasis","volume":"18","author":"Belmonte","year":"2017","journal-title":"Pharmacogenomics"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s40291-018-0345-9","article-title":"The Presence of HLA-A Bw4-80I KIR Ligands Could Predict \u201cDifficult-to-Treat\u201d Psoriasis and Poor Response to Etanercept","volume":"22","author":"Guarene","year":"2018","journal-title":"Mol. Diagn. Ther."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.2217\/pgs.15.90","article-title":"Association between TNF-\u03b1 (-308 A\/G, -238 A\/G, -857 C\/T) polymorphisms and responsiveness to TNF-\u03b1 blockers in spondyloarthropathy, psoriasis and Crohn\u2019s disease: A meta-analysis","volume":"16","author":"Song","year":"2015","journal-title":"Pharmacogenomics"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/BF03256427","article-title":"Pharmacogenetic Analysis of TNF, TNFRSF1A, and TNFRSF1B Gene Polymorphisms and Prediction of Response to Anti-TNF Therapy in Psoriasis Patients in the Greek Population","volume":"16","author":"Vasilopoulos","year":"2012","journal-title":"Mol. Diagn. Ther."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1111\/jdv.13024","article-title":"TNF-alpha gene polymorphisms can help to predict response to etanercept in psoriatic patients","volume":"29","author":"Farina","year":"2015","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_97","first-page":"146","article-title":"Functional study of TNF-\u03b1 as a promoter of polymorphisms in psoriasis","volume":"157","author":"Ponti","year":"2022","journal-title":"Ital. J. Dermatol. Venereol."},{"key":"ref_98","first-page":"e175","article-title":"Polymorphisms associated with anti-TNF drugs response in patients with psoriasis and psoriatic arthritis","volume":"33","author":"Reolid","year":"2019","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"e110","DOI":"10.1111\/1346-8138.15200","article-title":"Lack of association of TNFA, TNFRSF1B and TNFAIP3 gene polymorphisms with response to anti-tumor necrosis factor therapy in Japanese patients with psoriasis","volume":"47","author":"Ito","year":"2020","journal-title":"J. Dermatol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"401","DOI":"10.3389\/fcell.2020.00401","article-title":"Selective Targeting of TNF Receptors as a Novel Therapeutic Approach","volume":"8","author":"Fischer","year":"2020","journal-title":"Front. Cell Dev. Biol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s00403-014-1533-z","article-title":"The TNFRSF1B rs1061622 polymorphism (p.M196R) is associated with biological drug outcome in Psoriasis patients","volume":"307","author":"Batalla","year":"2015","journal-title":"Arch. Dermatol. Res."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.intimp.2015.05.049","article-title":"The tumor necrosis factor receptor superfamily member 1B polymorphisms predict response to anti-TNF therapy in patients with autoimmune disease: A meta-analysis","volume":"28","author":"Chen","year":"2015","journal-title":"Int. Immunopharmacol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1038\/jid.2011.376","article-title":"TNFAIP3 Gene Polymorphisms Are Associated with Response to TNF Blockade in Psoriasis","volume":"132","author":"Tejasvi","year":"2012","journal-title":"J. Investig. Dermatol."},{"key":"ref_104","first-page":"240","article-title":"The effect of TNFAIP3 gene polymorphism on disease susceptibility and response of etanercept in psoriatic patients","volume":"7","author":"Abbas","year":"2020","journal-title":"Eur. J. Mol. Clin. Med."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1001\/jamadermatol.2013.4632","article-title":"The Role of Fc\u03b3 Receptor Polymorphisms in the Response to Anti\u2013Tumor Necrosis Factor Therapy in Psoriasis: A Pharmacogenetic Study","volume":"149","author":"Guilabert","year":"2013","journal-title":"JAMA Dermatol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/tpj.2016.64","article-title":"New polymorphisms associated with response to anti-TNF drugs in patients with moderate-to-severe plaque psoriasis","volume":"18","author":"Cabaleiro","year":"2018","journal-title":"Pharmacogenom. J."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/tpj.2016.16","article-title":"FCGR3A-V158F polymorphism is a disease-specific pharmacogenetic marker for the treatment of psoriasis with Fc-containing TNF\u03b1 inhibitors","volume":"17","author":"Mendrinou","year":"2017","journal-title":"Pharmacogenom. J."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1001\/jamadermatol.2015.2818","article-title":"Influence of Fc\u03b3 Receptor Polymorphisms on Response to Anti\u2013Tumor Necrosis Factor Treatment in Psoriasis","volume":"151","author":"Batalla","year":"2015","journal-title":"JAMA Dermatol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"435","DOI":"10.2217\/pgs-2021-0019","article-title":"Exploring pharmacogenetic variants for predicting response to anti-TNF therapy in autoimmune diseases: A meta-analysis","volume":"22","author":"Antonatos","year":"2021","journal-title":"Pharmacogenomics"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1111\/1346-8138.13412","article-title":"Genetic prediction of the effectiveness of biologics for psoriasis treatment","volume":"43","author":"Nishikawa","year":"2016","journal-title":"J. Dermatol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1111\/exd.14215","article-title":"Genome-wide association analysis of psoriasis patients treated with anti-TNF drugs","volume":"29","author":"Sabador","year":"2020","journal-title":"Exp. Dermatol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"968935","DOI":"10.3389\/fphar.2022.968935","article-title":"Genome-wide association analysis of anti-TNF-\u03b1 treatment response in Chinese patients with psoriasis","volume":"13","author":"Ren","year":"2022","journal-title":"Front. Pharmacol."},{"key":"ref_113","first-page":"e271","article-title":"Polymorphisms associated with optimization of biological therapy through drug dose reduction in moderate-to-severe psoriasis","volume":"34","author":"Sabador","year":"2020","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_114","doi-asserted-by":"crossref","unstructured":"Bucalo, A., Rega, F., Zangrilli, A., Silvestri, V., Valentini, V., Scafetta, G., Marraffa, F., Grassi, S., Rogante, E., and Piccolo, A. (2020). Paradoxical Psoriasis Induced by Anti-TNF\u03b1 Treatment: Evaluation of Disease-Specific Clinical and Genetic Markers. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21217873"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1038\/tpj.2015.53","article-title":"Paradoxical psoriasiform reactions to anti-TNF\u03b1 drugs are associated with genetic polymorphisms in patients with psoriasis","volume":"16","author":"Cabaleiro","year":"2016","journal-title":"Pharmacogenom. J."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"adv00448","DOI":"10.2340\/00015555-3794","article-title":"DNA Copy Number Variation Associated with Anti-tumour Necrosis Factor Drug Response and Paradoxical Psoriasiform Reactions in Patients with Moderate-to-severe Psoriasis","volume":"101","author":"Reolid","year":"2021","journal-title":"Acta Derm. Venereol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1016\/S0140-6736(08)60725-4","article-title":"Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)","volume":"371","author":"Leonardi","year":"2008","journal-title":"Lancet"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1016\/S0140-6736(08)60726-6","article-title":"Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)","volume":"371","author":"Papp","year":"2008","journal-title":"Lancet"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1111\/bjd.15023","article-title":"Comparison of the 1- and 5-year effectiveness of adalimumab, etanercept and ustekinumab in patients with psoriasis in daily clinical practice: Results from the prospective BioCAPTURE registry","volume":"176","author":"Zweegers","year":"2017","journal-title":"Br. J. Dermatol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1111\/bjd.12331","article-title":"Pharmacogenetics of psoriasis: HLA-Cw6 but not LCE3B\/3C deletion nor TNFAIP3 polymorphism predisposes to clinical response to interleukin 12\/23 blocker ustekinumab","volume":"169","author":"Talamonti","year":"2013","journal-title":"Br. J. Dermatol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.jaad.2015.08.055","article-title":"HLA-C*06 and response to ustekinumab in Caucasian patients with psoriasis: Outcome and long-term follow-up","volume":"74","author":"Talamonti","year":"2016","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1111\/bjd.15387","article-title":"Role of the HLA-C*06 allele in clinical response to ustekinumab: Evidence from real life in a large cohort of European patients","volume":"177","author":"Talamonti","year":"2017","journal-title":"Br. J. Dermatol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1111\/bjd.13056","article-title":"Human leucocyte antigen-Cw6 as a predictor for clinical response to ustekinumab, an interleukin-12\/23 blocker, in C hinese patients with psoriasis: A retrospective analysis","volume":"171","author":"Chiu","year":"2014","journal-title":"Br. J. Dermatol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1159\/000441719","article-title":"IL12B (p40) Gene Polymorphisms Contribute to Ustekinumab Response Prediction in Psoriasis","volume":"232","author":"Galluzzo","year":"2016","journal-title":"Dermatology"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1684\/ejd.2017.3071","article-title":"Psoriasis pharmacogenetics: HLA-Cw*0602 as a marker of therapeutic response to ustekinumab","volume":"27","author":"Raposo","year":"2017","journal-title":"Eur. J. Dermatol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1056\/NEJMoa0810652","article-title":"Comparison of Ustekinumab and Etanercept for Moderate-to-Severe Psoriasis","volume":"362","author":"Griffiths","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1016\/j.jid.2016.06.631","article-title":"HLA-C*06:02 Allele and Response to IL-12\/23 Inhibition: Results from the Ustekinumab Phase 3 Psoriasis Program","volume":"136","author":"Li","year":"2016","journal-title":"J. Investig. Dermatol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1001\/jamadermatol.2019.0098","article-title":"Association of HLA-C*06:02 Status with Differential Response to Ustekinumab in Patients with Psoriasis: A Systematic Review and Meta-analysis","volume":"155","author":"Hannink","year":"2019","journal-title":"JAMA Dermatol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"7","DOI":"10.2147\/PTT.S161437","article-title":"Limited clinical utility of HLA-Cw6 genotyping for outcome prediction in psoriasis patients under ustekinumab therapy: A monocentric, retrospective analysis","volume":"8","author":"Anzengruber","year":"2018","journal-title":"Psoriasis Targets Ther."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1038\/tpj.2017.31","article-title":"Associations between functional polymorphisms and response to biological treatment in Danish patients with psoriasis","volume":"18","author":"Loft","year":"2018","journal-title":"Pharmacogenom. J."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.2217\/pgs.15.107","article-title":"The polymorphism rs763780 in the IL-17F gene is associated with response to biological drugs in patients with psoriasis","volume":"16","author":"Cabaleiro","year":"2015","journal-title":"Pharmacogenomics"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"157","DOI":"10.2217\/pgs-2016-0122","article-title":"Pharmacogenetics of ustekinumab in patients with moderate-to-severe plaque psoriasis","volume":"18","author":"Cabaleiro","year":"2017","journal-title":"Pharmacogenomics"},{"key":"ref_133","doi-asserted-by":"crossref","unstructured":"Nani, P., Ladopoulou, M., Papaioannou, E.H., Papagianni, E.D., Antonatos, C., Xiropotamos, P., Kapsoritakis, A., Potamianos, P.S., Karmiris, K., and Tzathas, C. (2023). Pharmacogenetic Analysis of the MIR146A rs2910164 and MIR155 rs767649 Polymorphisms and Response to Anti-TNF Treatment in Patients with Crohn\u2019s Disease and Psoriasis. Genes, 14.","DOI":"10.3390\/genes14020445"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"7","DOI":"10.2217\/pgs-2017-0143","article-title":"Polymor-phisms associated with adalimumab and infliximab response in moderate-to-severe plaque psoriasis","volume":"19","author":"Reolid","year":"2018","journal-title":"Pharmacogenomics"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/tpj.2016.70","article-title":"IL17RA gene variants and anti-TNF response among psoriasis patients","volume":"18","author":"Batalla","year":"2018","journal-title":"Pharmacogenom. J."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1111\/bjd.14461","article-title":"Common and rare CARD14 gene variants affect the antitumour necrosis factor response among patients with psoriasis","volume":"175","author":"Batalla","year":"2016","journal-title":"Br. J. Dermatol."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/j.intimp.2015.11.008","article-title":"CDKAL1 gene variants affect the anti-TNF response among Psoriasis patients","volume":"29","author":"Batalla","year":"2015","journal-title":"Int. Immunopharmacol."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1038\/tpj.2014.71","article-title":"Association of the PDE3A-SLCO1C1 locus with the response to anti-TNF agents in psoriasis","volume":"15","author":"Dauden","year":"2015","journal-title":"Pharmacogenom. J."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1097\/FPC.0b013e32834e5e7b","article-title":"\u2212174G\/C IL-6 gene promoter polymorphism predicts therapeutic response to TNF-\u03b1 blockers","volume":"22","author":"Bianchi","year":"2012","journal-title":"Pharm. Genom."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"815121","DOI":"10.3389\/fimmu.2021.815121","article-title":"Genome-Wide Association Study of Ustekinumab Response in Psoriasis","volume":"12","author":"Connell","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_141","doi-asserted-by":"crossref","unstructured":"Morelli, M., Galluzzo, M., Scarponi, C., Madonna, S., Scaglione, G.L., Girolomoni, G., Talamonti, M., Bianchi, L., and Albanesi, C. (2022). Allelic Variants of HLA-C Upstream Region, PSORS1C3, MICA, TNFA and Genes Involved in Epidermal Homeostasis and Barrier Function Influence the Clinical Response to Anti-IL-12\/IL-23 Treatment of Patients with Psoriasis. Vaccines, 10.","DOI":"10.3390\/vaccines10111977"},{"key":"ref_142","doi-asserted-by":"crossref","unstructured":"Sawyer, L.M., Malottki, K., Sabry-Grant, C., Yasmeen, N., Wright, E., Sohrt, A., Borg, E., and Warren, R.B. (2019). Assessing the relative efficacy of interleukin-17 and interleukin-23 targeted treatments for moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis of PASI response. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0220868"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"2546161","DOI":"10.1155\/2019\/2546161","article-title":"Short-Term Efficacy and Safety of IL-17, IL-12\/23, and IL-23 Inhibitors Brodalumab, Secukinumab, Ixekizumab, Ustekinumab, Guselkumab, Tildrakizumab, and Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials","volume":"2019","author":"Bai","year":"2019","journal-title":"J. Immunol. Res."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1111\/bjd.16705","article-title":"Secukinumab shows high efficacy irrespective of HLA-Cw6 status in patients with moderate-to-severe plaque-type psoriasis: SUPREME study","volume":"179","author":"Costanzo","year":"2018","journal-title":"Br. J. Dermatol."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1111\/bjd.18013","article-title":"Secukinumab shows high efficacy irrespective of HLA-Cw6 status in patients with moderate-to-severe plaque-type psoriasis: Results from extension phase of the SUPREME study","volume":"181","author":"Papini","year":"2019","journal-title":"Br. J. Dermatol."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"e274","DOI":"10.1111\/jdv.14808","article-title":"Therapy response was not altered by HLA-Cw6 status in psoriasis patients treated with secukinumab: A retrospective case series","volume":"32","author":"Anzengruber","year":"2018","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1080\/14712598.2020.1708897","article-title":"In which patients the best efficacy of secukinumab? Update of a real-life analysis after 136 weeks of treatment with secukinumab in moderate-to-severe plaque psoriasis","volume":"20","author":"Galluzzo","year":"2020","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1080\/14712598.2021.1862082","article-title":"HLA-Cw6 and other HLA-C alleles, as well as MICB-DT, DDX58, and TYK2 genetic variants associate with optimal response to anti-IL-17A treatment in patients with psoriasis","volume":"21","author":"Morelli","year":"2021","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1111\/jdv.15787","article-title":"Response to IL -17A inhibitors secukinumab and ixekizumab cannot be explained by genetic variation in the protein-coding and untranslated regions of the IL -17A gene: Results from a multicentre study of four European psoriasis cohorts","volume":"34","author":"Reek","year":"2020","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1038\/tpj.2017.21","article-title":"Cost-effectiveness of pharmacogenetic-guided treatment: Are we there yet?","volume":"17","author":"Verbelen","year":"2017","journal-title":"Pharmacogenom. J."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.tips.2014.05.004","article-title":"Epigenetic mechanisms of importance for drug treatment","volume":"35","author":"Ivanov","year":"2014","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/j.jid.2015.12.029","article-title":"Epigenome-Wide Association Analysis Identified Nine Skin DNA Methylation Loci for Psoriasis","volume":"136","author":"Zhou","year":"2016","journal-title":"J. Investig. Dermatol."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1111\/bjd.15504","article-title":"Epigenetic biomarkers associated with antitumour necrosis factor drug response in moderate-to-severe psoriasis","volume":"178","author":"Cabaleiro","year":"2018","journal-title":"Br. J. Dermatol."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1111\/exd.13790","article-title":"Histone modifications associated with biological drug response in moderate-to-severe psoriasis","volume":"27","author":"Reolid","year":"2018","journal-title":"Exp. Dermatol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/12\/9850\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:49:49Z","timestamp":1760125789000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/12\/9850"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,7]]},"references-count":154,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2023,6]]}},"alternative-id":["ijms24129850"],"URL":"https:\/\/doi.org\/10.3390\/ijms24129850","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,7]]}}}